Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hanne F. Harbo is active.

Publication


Featured researches published by Hanne F. Harbo.


Nature Genetics | 2007

Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis

Frida Lundmark; Kristina Duvefelt; Ellen Iacobaeus; Ingrid Kockum; Erik Wallström; Mohsen Khademi; Annette Bang Oturai; Lars P. Ryder; Janna Saarela; Hanne F. Harbo; Elisabeth G. Celius; Hugh Salter; Tomas Olsson; Jan Hillert

Multiple sclerosis is a chronic, often disabling, disease of the central nervous system affecting more than 1 in 1,000 people in most western countries. The inflammatory lesions typical of multiple sclerosis show autoimmune features and depend partly on genetic factors. Of these genetic factors, only the HLA gene complex has been repeatedly confirmed to be associated with multiple sclerosis, despite considerable efforts. Polymorphisms in a number of non-HLA genes have been reported to be associated with multiple sclerosis, but so far confirmation has been difficult. Here, we report compelling evidence that polymorphisms in IL7R, which encodes the interleukin 7 receptor α chain (IL7Rα), indeed contribute to the non-HLA genetic risk in multiple sclerosis, demonstrating a role for this pathway in the pathophysiology of this disease. In addition, we report altered expression of the genes encoding IL7Rα and its ligand, IL7, in the cerebrospinal fluid compartment of individuals with multiple sclerosis.


American Journal of Human Genetics | 2005

A high-density screen for linkage in multiple sclerosis.

Stephen Sawcer; Maria Ban; Mel Maranian; Tai Wai Yeo; Alastair Compston; Andrew Kirby; Mark J. Daly; De Jager Pl; Emily Walsh; Eric S. Lander; John D. Rioux; David A. Hafler; Adrian J. Ivinson; Jacqueline Rimmler; Simon G. Gregory; Silke Schmidt; Margaret A. Pericak-Vance; Eva Åkesson; Jan Hillert; Pameli Datta; Annette Bang Oturai; Lars P. Ryder; Hanne F. Harbo; Anne Spurkland; Kjell-Morten Myhr; Mikko Laaksonen; David R. Booth; Robert Heard; Graeme J. Stewart; Robin Lincoln

To provide a definitive linkage map for multiple sclerosis, we have genotyped the Illumina BeadArray linkage mapping panel (version 4) in a data set of 730 multiplex families of Northern European descent. After the application of stringent quality thresholds, data from 4,506 markers in 2,692 individuals were included in the analysis. Multipoint nonparametric linkage analysis revealed highly significant linkage in the major histocompatibility complex (MHC) on chromosome 6p21 (maximum LOD score [MLS] 11.66) and suggestive linkage on chromosomes 17q23 (MLS 2.45) and 5q33 (MLS 2.18). This set of markers achieved a mean information extraction of 79.3% across the genome, with a Mendelian inconsistency rate of only 0.002%. Stratification based on carriage of the multiple sclerosis-associated DRB1*1501 allele failed to identify any other region of linkage with genomewide significance. However, ordered-subset analysis suggested that there may be an additional locus on chromosome 19p13 that acts independent of the main MHC locus. These data illustrate the substantial increase in power that can be achieved with use of the latest tools emerging from the Human Genome Project and indicate that future attempts to systematically identify susceptibility genes for multiple sclerosis will have to involve large sample sizes and an association-based methodology.


Immunological Reviews | 2012

The genetics of multiple sclerosis: an up‐to‐date review

Pierre-Antoine Gourraud; Hanne F. Harbo; Stephen L. Hauser; Sergio E. Baranzini

Summary:  Multiple sclerosis (MS) is a prevalent inflammatory disease of the central nervous system that often leads to disability in young adults. Treatment options are limited and often only partly effective. The disease is likely caused by a complex interaction between multiple genes and environmental factors, leading to inflammatory‐mediated central nervous system deterioration. A series of genomic studies have confirmed a central role for the immune system in the development of MS, including genetic association studies that have now dramatically expanded the roster of MS susceptibility genes beyond the longstanding human leukocyte antigen (HLA) association in MS first identified nearly 40 years ago. Advances in technology together with novel models for collaboration across research groups have enabled the discovery of more than 50 non‐HLA genetic risk factors associated with MS. However, with a large proportion of the disease heritability still unaccounted for, current studies are now geared towards identification of causal alleles, associated pathways, epigenetic mechanisms, and gene–environment interactions. This article reviews recent efforts in addressing the genetics of MS and the challenges posed by an ever increasing amount of analyzable data, which is spearheading development of novel statistical methods necessary to cope with such complexity.


American Journal of Human Genetics | 2010

Genome-wide Association Study in a High-Risk Isolate for Multiple Sclerosis Reveals Associated Variants in STAT3 Gene

Eveliina Jakkula; Virpi Leppa; Anna-Maija Sulonen; Teppo Varilo; Suvi P. Kallio; Anu Kemppinen; Shaun Purcell; Keijo Koivisto; Pentti J. Tienari; Marja-Liisa Sumelahti; Irina Elovaara; Tuula Pirttilä; Mauri Reunanen; Arpo Aromaa; Annette Bang Oturai; Helle Bach Søndergaard; Hanne F. Harbo; Inger-Lise Mero; Stacey Gabriel; Daniel B. Mirel; Stephen L. Hauser; Ludwig Kappos; Chris H. Polman; Philip L. De Jager; David A. Hafler; Mark J. Daly; Aarno Palotie; Janna Saarela; Leena Peltonen

Genetic risk for multiple sclerosis (MS) is thought to involve both common and rare risk alleles. Recent GWAS and subsequent meta-analysis have established the critical role of the HLA locus and identified new common variants associated to MS. These variants have small odds ratios (ORs) and explain only a fraction of the genetic risk. To expose potentially rare, high-impact alleles, we conducted a GWAS of 68 distantly related cases and 136 controls from a high-risk internal isolate of Finland with increased prevalence and familial occurrence of MS. The top 27 loci with p < 10(-4) were tested in 711 cases and 1029 controls from Finland, and the top two findings were validated in 3859 cases and 9110 controls from more heterogeneous populations. SNP (rs744166) within the STAT3 gene was associated to MS (p = 2.75 x 10(-10), OR 0.87, confidence interval 0.83-0.91). The protective haplotype for MS in STAT3 is a risk allele for Crohn disease, implying that STAT3 represents a shared risk locus for at least two autoimmune diseases. This study also demonstrates the potential of special isolated populations in search for variants contributing to complex traits.


Genes and Immunity | 2009

The expanding genetic overlap between multiple sclerosis and type I diabetes

David R. Booth; Robert Heard; Graeme J. Stewart; An Goris; Rita Dobosi; Bénédicte Dubois; Åslaug R. Lorentzen; Elisabeth G. Celius; Hanne F. Harbo; Anne Spurkland; Tomas Olsson; Ingrid Kockum; Jenny Link; Jan Hillert; Maria Ban; Amie Baker; Stephen Sawcer; Alastair Compston; Tania Mihalova; Richard C. Strange; Clive Hawkins; Gillian Ingram; Neil Robertson; Philip L. De Jager; David A. Hafler; Lisa F. Barcellos; Adrian J. Ivinson; Margaret A. Pericak-Vance; Jorge R. Oksenberg; Stephen L. Hauser

Familial clustering of autoimmune disease is well recognized and raises the possibility that some susceptibility genes may predispose to autoimmunity in general. In light of this observation, it might be expected that some of the variants of established relevance in one autoimmune disease may also be relevant in other related conditions. On the basis of this hypothesis, we tested seven single nucleotide polymorphisms (SNPs) that are known to be associated with type I diabetes in a large multiple sclerosis data set consisting of 2369 trio families, 5737 cases and 10 296 unrelated controls. Two of these seven SNPs showed evidence of association with multiple sclerosis; that is rs12708716 from the CLEC16A gene (P=1.6 × 10−16) and rs763361 from the CD226 gene (P=5.4 × 10−8). These findings thereby identify two additional multiple sclerosis susceptibility genes and lend support to the notion of autoimmune susceptibility genes.


The American Journal of Medicine | 2001

Altered ovarian function and cardiovascular risk factors in valproate-treated women.

Jouko I. T. Isojärvi; Erik Taubøll; Arto Pakarinen; Johan van Parys; Johanna Rättyä; Hanne F. Harbo; Per O Dale; Bart C.J.M. Fauser; Leif Gjerstad; Riitta Koivunen; M. Knip; Juha S. Tapanainen

PURPOSE Polycystic ovaries and menstrual disturbances seem to be common among women taking valproate for epilepsy. The purpose of the present study was to assess the frequency of valproate-related metabolic and endocrine disorders in different groups of women with epilepsy. SUBJECTS AND METHODS Seventy-two women with epilepsy and 52 control subjects from centers in three European countries (Finland, Norway, and the Netherlands) participated in the study. Thirty-seven of the women with epilepsy were taking valproate monotherapy and 35 carbamazepine monotherapy. RESULTS The frequency of polycystic ovaries or hyperandrogenism, or both, among valproate-treated women with epilepsy was 70% (26 of 37) compared with 19% (10 of 52) among control subjects (P <0.001). They were found in 79% (11 of 14) of obese and 65% (15 of 23) of lean women on valproate, and in 20% (7 of 35) of carbamazepine-treated women. The obese valproate-treated women with polycystic ovaries or hyperandrogenism, or both, had hyperinsulinemia and associated unfavorable changes in serum lipid levels consistent with insulin resistance. CONCLUSIONS Polycystic ovaries and related hyperandrogenism are frequently encountered in both obese and lean women taking valproate for epilepsy. The use of valproate is associated with risk factors for cardiovascular disease in obese women.


American Journal of Human Genetics | 2013

Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls

Sergio E. Baranzini; Pouya Khankhanian; Nikolaos A. Patsopoulos; Michael Li; Jim Stankovich; Chris Cotsapas; Helle Bach Søndergaard; Maria Ban; Nadia Barizzone; Laura Bergamaschi; David R. Booth; Dorothea Buck; Paola Cavalla; Elisabeth G. Celius; Manuel Comabella; Giancarlo Comi; Alastair Compston; Isabelle Cournu-Rebeix; Sandra D’Alfonso; Vincent Damotte; Lennox Din; Bénédicte Dubois; Irina Elovaara; Federica Esposito; Bertrand Fontaine; Andre Franke; An Goris; Pierre-Antoine Gourraud; Christiane Graetz; Franca Rosa Guerini

Multiple sclerosis (MS) is an inflammatory CNS disease with a substantial genetic component, originally mapped to only the human leukocyte antigen (HLA) region. In the last 5 years, a total of seven genome-wide association studies and one meta-analysis successfully identified 57 non-HLA susceptibility loci. Here, we merged nominal statistical evidence of association and physical evidence of interaction to conduct a protein-interaction-network-based pathway analysis (PINBPA) on two large genetic MS studies comprising a total of 15,317 cases and 29,529 controls. The distribution of nominally significant loci at the gene level matched the patterns of extended linkage disequilibrium in regions of interest. We found that products of genome-wide significantly associated genes are more likely to interact physically and belong to the same or related pathways. We next searched for subnetworks (modules) of genes (and their encoded proteins) enriched with nominally associated loci within each study and identified those modules in common between the two studies. We demonstrate that these modules are more likely to contain genes with bona fide susceptibility variants and, in addition, identify several high-confidence candidates (including BCL10, CD48, REL, TRAF3, and TEC). PINBPA is a powerful approach to gaining further insights into the biology of associated genes and to prioritizing candidates for subsequent genetic studies of complex traits.


Journal of the Neurological Sciences | 2000

Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis

Elisabeth G. Celius; Hanne F. Harbo; T Egeland; Frode Vartdal; B. Vandvik; A Spurkiand

The HLA-DR2, DQ6 (i.e., HLA-DRB1*1501, DQA1*0102, DQB1*0602) haplotype contributes to the risk of developing multiple sclerosis (MS) in Caucasoids of Northern European heritage. A correlation between the clinical expression of MS and the presence of HLA-DR2, DQ6 has, however, not convincingly been shown. In this study conventional bivariate analysis and logistic regression analysis were used to study the relationship between HLA-DR2, DQ6 and four disease variables in a cohort of 286 Norwegian MS patients from the Oslo area. Logistic regression analysis showed that HLA-DR2, DQ6 was significantly more frequent among female than male patients (P=0. 0251), and was negatively correlated with age at diagnosis regardless of sex (P=0.0254). No significant correlation was observed between HLA-DR2, DQ6 and type of disease (relapsing-remitting versus primary chronic progressive MS) or presence/absence of oligoclonal bands in the cerebrospinal fluid.


European Journal of Human Genetics | 2009

Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor

Maria Ban; An Goris; Åslaug R. Lorentzen; Amie Baker; Tania Mihalova; Gillian Ingram; David R. Booth; Robert Heard; Graeme J. Stewart; Elke Bogaert; Bénédicte Dubois; Hanne F. Harbo; Elisabeth G. Celius; Anne Spurkland; Richard C. Strange; Clive Hawkins; Neil Robertson; Frank Dudbridge; James Wason; Philip L. De Jager; David A. Hafler; John D. Rioux; Adrian J. Ivinson; Jacob L. McCauley; Margaret A. Pericak-Vance; Jorge R. Oksenberg; Stephen L. Hauser; David M. H. Sexton; Jonathan L. Haines; Stephen Sawcer

In a recent genome-wide association study (GWAS) based on 12 374 non-synonymous single nucleotide polymorphisms we identified a number of candidate multiple sclerosis susceptibility genes. Here, we describe the extended analysis of 17 of these loci undertaken using an additional 4234 patients, 2983 controls and 2053 trio families. In the final analysis combining all available data, we found that evidence for association was substantially increased for one of the 17 loci, rs34536443 from the tyrosine kinase 2 (TYK2) gene (P=2.7 × 10−6, odds ratio=1.32 (1.17–1.47)). This single nucleotide polymorphism results in an amino acid substitution (proline to alanine) in the kinase domain of TYK2, which is predicted to influence the levels of phosphorylation and therefore activity of the protein and so is likely to have a functional role in multiple sclerosis.


Molecular Psychiatry | 2015

Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci

Ole A. Andreassen; Hanne F. Harbo; Yunpeng Wang; Wesley K. Thompson; Andrew J. Schork; Morten Mattingsdal; Zuber; Francesco Bettella; Stephan Ripke; John R. Kelsoe; Kenneth S. Kendler; Michael Conlon O'Donovan; Pamela Sklar; Linda K. McEvoy; Rahul S. Desikan; Benedicte A. Lie; Srdjan Djurovic; Anders M. Dale

Converging evidence implicates immune abnormalities in schizophrenia (SCZ), and recent genome-wide association studies (GWAS) have identified immune-related single-nucleotide polymorphisms (SNPs) associated with SCZ. Using the conditional false discovery rate (FDR) approach, we evaluated pleiotropy in SNPs associated with SCZ (n=21 856) and multiple sclerosis (MS) (n=43 879), an inflammatory, demyelinating disease of the central nervous system. Because SCZ and bipolar disorder (BD) show substantial clinical and genetic overlap, we also investigated pleiotropy between BD (n=16 731) and MS. We found significant genetic overlap between SCZ and MS and identified 21 independent loci associated with SCZ, conditioned on association with MS. This enrichment was driven by the major histocompatibility complex (MHC). Importantly, we detected the involvement of the same human leukocyte antigen (HLA) alleles in both SCZ and MS, but with an opposite directionality of effect of associated HLA alleles (that is, MS risk alleles were associated with decreased SCZ risk). In contrast, we found no genetic overlap between BD and MS. Considered together, our findings demonstrate genetic pleiotropy between SCZ and MS and suggest that the MHC signals may differentiate SCZ from BD susceptibility.

Collaboration


Dive into the Hanne F. Harbo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kjell-Morten Myhr

Haukeland University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

An Goris

Katholieke Universiteit Leuven

View shared research outputs
Researchain Logo
Decentralizing Knowledge